Literature DB >> 33712110

Simultaneous appendage ligation and atrial ablation - is it worth the risk?

Jalaj Garg1, Dhanunjaya Lakkireddy2.   

Abstract

Entities:  

Year:  2021        PMID: 33712110      PMCID: PMC7952887          DOI: 10.1016/j.ipej.2021.02.011

Source DB:  PubMed          Journal:  Indian Pacing Electrophysiol J        ISSN: 0972-6292


× No keyword cloud information.
Electrical isolation of pulmonary veins remains the mainstay for the treatment of atrial fibrillation (AF). Optimal ablation lesion set in persistent AF and long-standing persistent AF remains unknown and failed to demonstrate superiority beyond stand-alone pulmonary vein isolation (PVI) [1]. Left atrial appendage (LAA) has been increasingly recognized as an important source of non-PV triggers and reentry [2,3]. Hence, electrical isolation of LAA as an adjunct to PVI may significantly decrease the recurrence of AF [4]. However, the procedural complexity, potential risk of perforation, significant (>50%) reconnection rates, and systemic thromboembolism after LAA isolation remain a critical concern [[5], [6], [7]]. Electrical isolation of LAA impairs its mechanical contractility – increases blood stasis and risk of thrombus formation (above and beyond stand-alone PVI with electrically intact LAA). This increases LAA thrombus risk and systemic embolization despite continued oral anticoagulation in some cases and demands uninterrupted oral anticoagulation, possibly occlusion for stroke protection despite successful AF rhythm control after an ablation. A strategy of sequential LAA ligation followed by PVI has shown to improve ablation outcomes, and a randomized control trial has recently been completed with results pending [8,9]. Sequential LAA ligation and ablation during two separate procedures has been the common strategy, however, simultaneous LAA ligation and ablation during the same procedure has not been studied. In this issue of Indian Pacing and Electrophysiology, Nentwich et al. report safety and long-term outcomes of concomitant AF ablation with LAA ligation with endoepicardial system (Lariat device) in a single procedure in a very small cohort [10]. Nine patients (mean age 67 ± 10 years, normal left ventricular systolic function, mean CHA2DS2VASc 4 ± 1.1 and HAS-BLED score 2.1 ± 0.78) with long-standing persistent AF underwent PVI and additional ablation (at operator discretion based on high-density bipolar voltage map) and concomitant Lariat device (LAA ligation) at high volume highly trained center in Europe. The study demonstrated 100% acute procedure success in LAA ligation with no intraprocedural LAA flow on transesophageal echocardiogram. There were no major acute procedural complications. All patients received three months of oral anticoagulation and six weeks of colchicine. 33% (n = 3) patients experienced major complications – non-disabling stroke (deemed not procedure-related and with no flow across LAA at 14 weeks), dressler's syndrome, and pericardial tamponade (due to prolonged pericardial inflammation, requiring pericardiocentesis). At 12 months follow-up, a transesophageal echocardiogram demonstrated no flow across in LAA in all patients, with arrhythmia-free survival in 78% of patients (n = 7), and the remaining 22% of patients (n = 2) had a significant reduction in AF burden. The current study is undoubtedly of great interest due to its timely clinical relevance. However, there are several drawbacks beyond its extremely small sample size. While the idea of shooting two birds with one shot is very attractive, this initial experience clearly shows that it may not be worth the effort. The most compelling reasons for combining these two complex procedures are several folds. Both procedures share similar procedure steps (at least endocardially, besides apparent epicardial access); a combination procedure may potentially reduce the risk of procedure-related complications (vascular access, anticoagulation, access to the left atrium via transseptal approach), general anesthesia. In addition, patients would require a shorter duration on oral anticoagulation, fewer hospitalization, patient convenience, and overall reduced health care costs. This logic may be great for discussion, but the evidence is contrary. While there were no acute intraprocedural complications, there were significant subacute complications. The learning curve is definitely steep for operators who are not facile with routine dry pericardial access. Careful patient selection, preprocedural imaging, micropuncture epicardial access technique [11] and experience have been shown to improve overall procedure safety and mitigate complications. The procedure duration will be significantly longer, increasing the overall general anesthesia times. One major issue will be related to oral anticoagulation. Ligating LAA on uninterrupted oral anticoagulation could significantly increase intraprocedural bleeding complications. The ongoing LAA tissue necrosis combined with continued OAC could increase the risk of hemorrhagic pericarditis and increased subacute tamponade. This risk becomes even higher when extensive ablation of the left atrium, especially the posterior wall, is performed for most of these long-standing persistent AF patients. It becomes a perfect set up long-term issues related to pericarditis. The other factor that the authors did not comment on are the neurohormonal and hemodynamic changes that most of the patients who undergo LAA exclusion with a Lariat or AtriClip or surgical ligation experience. Patients often experience neurohormonally driven systemic hypotension, pre-renal syndrome with transient fluid retention that could complicate the clinical course [[12], [13], [14], [15]]. While the aMAZE trial may answer the added value of LAA ligation to ablation strategy for rhythm control in non-paroxysmal AF patients, it will not answer whether a simultaneous LAA ligation and ablation strategy is superior to the sequential approach that was used in that study. Based on our clinical experience and the relatively higher combined morbidity of these two procedures suggest that combining these two procedures may not be in the best interest of patient outcomes. 33% subacute complication rate despite excellent procedural performance clearly points dramatically increased patient morbidity from combining these two complex procedures. As our experience has taught us over the last decade, a sequential approach will help us to safely perform adjunctive electromechanical LAA isolation while improving the efficacy of AF ablation.
  15 in total

1.  Epicardial Left Atrial Appendage Exclusion Reduces Blood Pressure in Patients With Atrial Fibrillation and Hypertension.

Authors:  Mohit K Turagam; Venkat Vuddanda; Niels Verberkmoes; Toshiya Ohtsuka; Ferdi Akca; Donita Atkins; Sudharani Bommana; Maximilian Y Emmert; Rakesh Gopinathannair; Gansevoort Dunnington; Abdi Rasekh; Jie Cheng; Sacha Salzberg; Andrea Natale; James Cox; Dhanunjaya R Lakkireddy
Journal:  J Am Coll Cardiol       Date:  2018-09-18       Impact factor: 24.094

2.  Differences in complication rates between large bore needle and a long micropuncture needle during epicardial access: time to change clinical practice?

Authors:  Sampath Gunda; Madhu Reddy; Jayasree Pillarisetti; Moustapha Atoui; Nitish Badhwar; Vijay Swarup; Luigi DiBiase; Sanghamitra Mohanty; Prashanth Mohanty; Hosakote Nagaraj; Christopher Ellis; Abdi Rasekh; Jie Cheng; Krzysztof Bartus; Randall Lee; Andrea Natale; Dhanunjaya Lakkireddy
Journal:  Circ Arrhythm Electrophysiol       Date:  2015-06-15

3.  Electrolyte and hemodynamic changes following percutaneous left atrial appendage ligation with the LARIAT device.

Authors:  Ryan Maybrook; Jayasree Pillarisetti; Vivek Yarlagadda; Sampath Gunda; Arun Raghav Mahankali Sridhar; Brent Deibert; Muhammad R Afzal; Madhu Reddy; Donita Atkins; Matthew Earnest; Ryan Ferrell; Jayant Nath; Arun Kanmanthareddy; Sudharani Bommana; Rajasingh Johnson; Sandeep Reddy Koripalli; Buddhadeb Dawn; Dhanunjaya Lakkireddy
Journal:  J Interv Card Electrophysiol       Date:  2015-05-09       Impact factor: 1.900

4.  Electrical isolation of the left atrial appendage by Maze-like catheter substrate modification: A reproducible strategy for pulmonary vein isolation nonresponders?

Authors:  Stefano Bordignon; Laura Perrotta; Daniela Dugo; Fabrizio Bologna; Takahiko Nagase; Alexander Fuernkranz; K R Julian Chun; Boris Schmidt
Journal:  J Cardiovasc Electrophysiol       Date:  2017-07-26

5.  The effects of LAA ligation on LAA electrical activity.

Authors:  Frederick T Han; Krzysztof Bartus; Dhanunjaya Lakkireddy; Francia Rojas; Jacek Bednarek; Boguslaw Kapelak; Magdalena Bartus; Jerzy Sadowski; Nitish Badhwar; Mathew Earnest; Miguel Valderrabano; Randall J Lee
Journal:  Heart Rhythm       Date:  2014-01-18       Impact factor: 6.343

6.  Left Atrial Appendage Closure and Systemic Homeostasis: The LAA HOMEOSTASIS Study.

Authors:  Dhanunjaya Lakkireddy; Mohit Turagam; Muhammad Rizwan Afzal; Johnson Rajasingh; Donita Atkins; Buddhadeb Dawn; Luigi Di Biase; Krzysztof Bartus; Saibal Kar; Andrea Natale; David J Holmes
Journal:  J Am Coll Cardiol       Date:  2018-01-16       Impact factor: 24.094

7.  Approaches to catheter ablation for persistent atrial fibrillation.

Authors:  Atul Verma; Chen-yang Jiang; Timothy R Betts; Jian Chen; Isabel Deisenhofer; Roberto Mantovan; Laurent Macle; Carlos A Morillo; Wilhelm Haverkamp; Rukshen Weerasooriya; Jean-Paul Albenque; Stefano Nardi; Endrj Menardi; Paul Novak; Prashanthan Sanders
Journal:  N Engl J Med       Date:  2015-05-07       Impact factor: 91.245

8.  Left Atrial Appendage Ligation and Ablation for Persistent Atrial Fibrillation: The LAALA-AF Registry.

Authors:  Dhanunjaya Lakkireddy; Arun Sridhar Mahankali; Arun Kanmanthareddy; Randall Lee; Nitish Badhwar; Krzysztof Bartus; Donita Atkins; Sudharani Bommana; Jie Cheng; Abdi Rasekh; Luigi Di Biase; Andrea Natale; Jayant Nath; Ryan Ferrell; Matthew Earnest; Yeruva Madhu Reddy
Journal:  JACC Clin Electrophysiol       Date:  2015-04-30

Review 9.  Role of the Left Atrial Appendage in Systemic Homeostasis, Arrhythmogenesis, and Beyond.

Authors:  Ghulam Murtaza; Bharath Yarlagadda; Krishna Akella; Domenico G Della Rocca; Rakesh Gopinathannair; Andrea Natale; Dhanunjaya Lakkireddy
Journal:  Card Electrophysiol Clin       Date:  2020-03

10.  Percutaneous alternative to the Maze procedure for the treatment of persistent or long-standing persistent atrial fibrillation (aMAZE trial): Rationale and design.

Authors:  Randall J Lee; Dhanunjaya Lakkireddy; Suneet Mittal; Christopher Ellis; Jason T Connor; Benjamin R Saville; David Wilber
Journal:  Am Heart J       Date:  2015-10-03       Impact factor: 4.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.